DNA-HIV-PT123 clinical trials
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2013
How each study uses DNA-HIV-PT123 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- DNA-HIV-PT123 vaccine
- 5
Studies by the year they started
4 studies that test it; most in 2016 (2)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 1 |
| 2016 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 5
National Institute of Allergy and Infectious Diseases (NIAID) (5)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses DNA-HIV-PT123 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected AdultsCompletedPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT02915016Written as DNA-HIV-PT123 vaccine
- Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected AdultsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT02207920Written as DNA-HIV-PT123 Vaccine
- Evaluating the Safety and Immune Response to Three HIV Vaccine Schedules in Healthy, HIV-Uninfected AdultsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT01783977Written as DNA-HIV-PT123 vaccine
- Evaluating the Safety and Immune Response to Two HIV Vaccine Regimens in Healthy, HIV-Uninfected Adults in the United States and South AfricaWithdrawnPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT01927835Written as DNA-HIV-PT123 vaccine
- Safety and Immune Response to a Clade C DNA HIV VaccineCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT02997969Written as DNA-HIV-PT123 vaccine